BridgeBio, BMS to develop and commercialize SHP2 inhibitor BBP-398

GSK and LTZ collaborate to advance novel myeloid cell engagers in oncology

GSK and LTZ Therapeutics, an immunotherapy-focused biotechnology company based in Redwood City, CA, will collaborate to advance the development of novel myeloid cell engagers.

November 21, 2025

Vol.51 No.43

Drugs & Targets

Freenome and Roche to expand collaboration to develop and commercialize cancer screening tests outside the U.S.

Freenome, an early cancer detection company, and Roche announced a collaboration agreement to commercialize Freenome’s cancer screening technology in international markets.

November 21, 2025

Vol.51 No.43

Drugs & Targets

Microsoft and Qure.ai collaborate to accelerate AI lung cancer detection

Microsoft and Qure.ai announced a collaboration that will streamline deployment of Qure.ai solutions to hospitals and health systems across the U.S.

November 21, 2025

Vol.51 No.43

Drugs & Targets

Cue Biopharma and ImmunoScape collaborate to develop cell therapy approach for solid tumors

Cue Biopharma, a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, and ImmunoScape, a biotechnology company developing next-generation T cell receptor-based therapies in oncology, announced that they have entered into a collaboration and license agreement to advance a novel in vivo approach to cell therapy for the treatment of solid tumors.

November 14, 2025

Vol.51 No.42

City of Hope’s leadership in lung cancer: Precision, innovation, and a vision for cure

As we mark Lung Cancer Awareness Month, it is a time to acknowledge that screening and prevention are vital, and equally crucial is ensuring that patients have access to state-of-the-art care and research. Herein, I spotlight some of the transformative work underway at City of Hope.

November 07, 2025

Vol.51 No.41

By Ravi Salgia

News Analysis Regulatory News

Trump’s FDA invents an unusual regulatory pathway to approve leucovorin for autism
Experts call the move “extremely premature”

FDA has initiated the approval of leucovorin calcium tablets, rushing them to market as part of a push from the Trump administration to identify potential treatments for autism spectrum disorder.

September 26, 2025

Vol.51 No.35

By Claire Marie Porter and Paul Goldberg

BridgeBio, BMS to develop and commercialize SHP2 inhibitor BBP-398

YOU MAY BE INTERESTED IN

GSK and LTZ collaborate to advance novel myeloid cell engagers in oncology

Freenome and Roche to expand collaboration to develop and commercialize cancer screening tests outside the U.S.

Microsoft and Qure.ai collaborate to accelerate AI lung cancer detection

Cue Biopharma and ImmunoScape collaborate to develop cell therapy approach for solid tumors

City of Hope’s leadership in lung cancer: Precision, innovation, and a vision for cure

Trump’s FDA invents an unusual regulatory pathway to approve leucovorin for autism
Experts call the move “extremely premature”

Renew today!

Subscriber content

Never miss an issue!

Login

BridgeBio, BMS to develop and commercialize SHP2 inhibitor BBP-398

YOU MAY BE INTERESTED IN

GSK and LTZ collaborate to advance novel myeloid cell engagers in oncology

Freenome and Roche to expand collaboration to develop and commercialize cancer screening tests outside the U.S.

Microsoft and Qure.ai collaborate to accelerate AI lung cancer detection

Cue Biopharma and ImmunoScape collaborate to develop cell therapy approach for solid tumors

City of Hope’s leadership in lung cancer: Precision, innovation, and a vision for cure

Trump’s FDA invents an unusual regulatory pathway to approve leucovorin for autismExperts call the move “extremely premature”

Never miss an issue!

Login

Trump’s FDA invents an unusual regulatory pathway to approve leucovorin for autism
Experts call the move “extremely premature”